Area of research
Pharmacology · Psychiatry and Mental health
Research interest
Research interests include Treatment of Major Depression, Schizophrenia research and treatment, Tryptophan and brain disorders, and Bipolar Disorder and Treatment.
Mild motor signs and depression: more than just medication side effects?
Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine.
Neuropsychiatric manifestations of primary hyperparathyroidism.
Expert consensus on the use of trazodone in patients with major depressive disorder: results from a European Delphi panel.
Hindrance to precision psychiatry: more sex-specific investigations needed.
The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus.
Correction: Mild motor signs and depression: more than just medication side effects?
TROPHIT1—a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients
Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis.
Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data.
Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial.
In vivo serotonin 1A receptor distribution in treatment-resistant depression.
Symptom networks in major depressive disorder and treatment response: special focus on TRD.
In memoriam: Professor Dan J. Stein (1962-2025) — a global pioneer with an African heart
Oral Ketamine for the Treatment of Depression: A randomized controlled trial and meta-analysis
Siegfried Kasper: The importance of back-translation of clinical findings to basic science
Anhedonia is associated with a specific depression profile and poor antidepressant response.
Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials.
KET or ECT for treatment-resistant depression?
Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
Subthreshold depression - concept, operationalisation and epidemiological data. A scoping review.
Effects of bilateral sequential theta-burst stimulation on functional connectivity in treatment-resistant depression: First results.
Reply to: "The serotonin theory of depression: a systematic umbrella review of the evidence" published by Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA in Molecular Psychiatry (2022 Jul 20. doi: 10.1038/s41380-022-01661-0).
Effects of bilateral sequential theta-burst stimulation on 5-HT<sub>1A</sub> receptors in the dorsolateral prefrontal cortex in treatment-resistant depression: a proof-of-concept trial.
Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.
Age as a moderating factor of treatment resistance in depression.
Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan.
Silexan for treatment of anxiety and depression in the context of COVID-19.
Factors associated with sick leave duration in patients suffering from major depressive disorder initiating antidepressant treatment: a real-world evidence study in Germany and Spain.